1. Home
  2. RDNT vs ACAD Comparison

RDNT vs ACAD Comparison

Compare RDNT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RadNet Inc.

RDNT

RadNet Inc.

HOLD

Current Price

$54.33

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.51

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDNT
ACAD
Founded
1985
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.8B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
RDNT
ACAD
Price
$54.33
$21.51
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$82.80
$30.55
AVG Volume (30 Days)
787.6K
1.4M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
$1,616,630,000.00
$726,437,000.00
Revenue This Year
$22.78
$18.80
Revenue Next Year
$10.70
$11.70
P/E Ratio
N/A
$1,086.08
Revenue Growth
13.05
40.45
52 Week Low
$50.79
$19.69
52 Week High
$85.84
$28.35

Technical Indicators

Market Signals
Indicator
RDNT
ACAD
Relative Strength Index (RSI) 47.25 49.69
Support Level $51.97 $21.12
Resistance Level $55.99 $22.03
Average True Range (ATR) 2.17 0.62
MACD 0.05 0.05
Stochastic Oscillator 58.13 74.70

Price Performance

Historical Comparison
RDNT
ACAD

About RDNT RadNet Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: